Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers